Indicated for: Moderate-to-severe acute pain
Status: In market (US)
Rights: Ortho-McNeil

Nucynta^® is a centrally acting oral analgesic that is indicated for the management of moderate to severe pain in patients 18 years of age or older. Under the terms of an agreement between NPS Pharmaceuticals and Ortho-McNeil Pharmaceutical Inc. ("Ortho-McNeil"), NPS is entitled to royalties on product sales of tapentadol hydrochloride.